Nils Wetzstein , Victor Naestholt Dahl , Troels Lillebaek , Christoph Lange
{"title":"Clinical spectrum and relevance of Mycobacterium malmoense: Systematic review and meta-analysis of 859 patients","authors":"Nils Wetzstein , Victor Naestholt Dahl , Troels Lillebaek , Christoph Lange","doi":"10.1016/j.jinf.2024.106203","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>The clinical relevance of <em>Mycobacterium malmoense</em> isolation from pulmonary specimens has been considered high compared with other non-tuberculous mycobacteria. In this study, we aimed to analyse all published clinical data of patients with <em>M. malmoense</em> isolation to investigate the clinical spectrum, relevance, and outcomes of infections with this uncommon mycobacterium.</p></div><div><h3>Methods</h3><p>A systematic review of PubMed, Web of Science, Embase, and Scopus was performed to identify all clinical data about <em>M. malmoense</em>. Random effects meta-analyses of proportions were calculated for clinical relevance, treatment success, and mortality, as well as for other clinical characteristics. A logistic regression analysis, investigating predictors of mortality, as well as Kaplan-Meier survival analyses, were performed.</p></div><div><h3>Results</h3><p>One hundred and eighty eight patients with individual data from 112 articles and 671 patients with pooled data from 12 articles were included in the meta-analyses. Of patients with individual data, pulmonary infection was the most common manifestation (n = 106/188, 56.4%). One third (n = 61/188, 32.4%) suffered from isolated extra-pulmonary and 21/188 (11.2%) from disseminated disease. In 288 patients with pooled data and pulmonary affection, clinical relevance was high with 68% (95% CI 44–85%) of patients fulfilling criteria for clinical disease. Macrolide and rifamycin-containing regimens were associated with improved survival (adjusted OR 0.12, 95% CI 0.03–0.42, p = 0.002, and 0.23, 95% CI 0.04–0.86, p = 0.03, for lethal events, respectively).</p></div><div><h3>Conclusion</h3><p>In this study, we provide a detailed clinical description of <em>M. malmoense</em> infections. The pathogen is of high clinical relevance for the individual patient with more than 2 out of 3 patients having relevant disease and >40% of manifestations being extra-pulmonary or disseminated. Macrolide and rifamycin-containing regimens are associated with improved survival.</p></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":null,"pages":null},"PeriodicalIF":14.3000,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324001373/pdfft?md5=d83d1e09dea2a4d86b5837f91075e1c4&pid=1-s2.0-S0163445324001373-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infection","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0163445324001373","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
The clinical relevance of Mycobacterium malmoense isolation from pulmonary specimens has been considered high compared with other non-tuberculous mycobacteria. In this study, we aimed to analyse all published clinical data of patients with M. malmoense isolation to investigate the clinical spectrum, relevance, and outcomes of infections with this uncommon mycobacterium.
Methods
A systematic review of PubMed, Web of Science, Embase, and Scopus was performed to identify all clinical data about M. malmoense. Random effects meta-analyses of proportions were calculated for clinical relevance, treatment success, and mortality, as well as for other clinical characteristics. A logistic regression analysis, investigating predictors of mortality, as well as Kaplan-Meier survival analyses, were performed.
Results
One hundred and eighty eight patients with individual data from 112 articles and 671 patients with pooled data from 12 articles were included in the meta-analyses. Of patients with individual data, pulmonary infection was the most common manifestation (n = 106/188, 56.4%). One third (n = 61/188, 32.4%) suffered from isolated extra-pulmonary and 21/188 (11.2%) from disseminated disease. In 288 patients with pooled data and pulmonary affection, clinical relevance was high with 68% (95% CI 44–85%) of patients fulfilling criteria for clinical disease. Macrolide and rifamycin-containing regimens were associated with improved survival (adjusted OR 0.12, 95% CI 0.03–0.42, p = 0.002, and 0.23, 95% CI 0.04–0.86, p = 0.03, for lethal events, respectively).
Conclusion
In this study, we provide a detailed clinical description of M. malmoense infections. The pathogen is of high clinical relevance for the individual patient with more than 2 out of 3 patients having relevant disease and >40% of manifestations being extra-pulmonary or disseminated. Macrolide and rifamycin-containing regimens are associated with improved survival.
导言:与其他非结核分枝杆菌相比,从肺部标本中分离出的恶性分枝杆菌被认为具有很高的临床意义。在本研究中,我们旨在分析所有已发表的关于分离出malmoense分枝杆菌患者的临床数据,以研究这种不常见分枝杆菌感染的临床范围、相关性和结果:方法:对PubMed、Web of Science、Embase和Scopus进行了系统性回顾,以确定所有关于M. malmoense的临床数据。对临床相关性、治疗成功率、死亡率以及其他临床特征进行了随机效应荟萃分析。对死亡率的预测因素进行了逻辑回归分析,并进行了卡普兰-梅耶生存分析:荟萃分析纳入了112篇文章中188名患者的个人数据和12篇文章中671名患者的集合数据。在有个体数据的患者中,肺部感染是最常见的表现(n=106/188,56.4%)。三分之一(n=61/188,32.4%)的患者患有孤立的肺外感染,21/188(11.2%)的患者患有播散性疾病。在汇集数据的288例肺部感染患者中,68%(95% CI 44-85%)的患者符合临床疾病标准,临床相关性很高。含大环内酯和利福霉素的治疗方案与生存率的提高有关(致死事件的调整OR值分别为0.12,95% CI 0.03-0.42,p=0.002和0.23,95% CI 0.04-0.86,p=0.03):在这项研究中,我们对M. malmoense感染进行了详细的临床描述。该病原体与个别患者的临床相关性很高,每3名患者中就有2名以上患有相关疾病,40%以上的表现为肺外或播散。含大环内酯类和利福霉素的治疗方案可提高存活率。
期刊介绍:
The Journal of Infection publishes original papers on all aspects of infection - clinical, microbiological and epidemiological. The Journal seeks to bring together knowledge from all specialties involved in infection research and clinical practice, and present the best work in the ever-changing field of infection.
Each issue brings you Editorials that describe current or controversial topics of interest, high quality Reviews to keep you in touch with the latest developments in specific fields of interest, an Epidemiology section reporting studies in the hospital and the general community, and a lively correspondence section.